AbbVie Inc. (ABBV)
USD 198.47
(2.65%)
USD 198.47
(2.65%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 124.31 Billion USD | 2.3% |
| 2022 | 121.51 Billion USD | -7.3% |
| 2021 | 131.09 Billion USD | -4.64% |
| 2020 | 137.46 Billion USD | 41.3% |
| 2019 | 97.28 Billion USD | 43.5% |
| 2018 | 67.79 Billion USD | 3.21% |
| 2017 | 65.68 Billion USD | 6.88% |
| 2016 | 61.46 Billion USD | 25.17% |
| 2015 | 49.1 Billion USD | 90.29% |
| 2014 | 25.8 Billion USD | 4.45% |
| 2013 | 24.7 Billion USD | 4.49% |
| 2012 | 23.64 Billion USD | 218.09% |
| 2011 | 7.43 Billion USD | 36.85% |
| 2010 | 5.43 Billion USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 135.11 Billion USD | -4.06% |
| 2024 Q1 | 140.82 Billion USD | 13.28% |
| 2024 Q3 | -6.82 Billion USD | 1.65% |
| 2023 Q1 | 121.24 Billion USD | -0.23% |
| 2023 Q2 | 122.46 Billion USD | 1.01% |
| 2023 FY | 124.31 Billion USD | 2.3% |
| 2023 Q3 | 124.09 Billion USD | 1.33% |
| 2023 Q4 | 124.31 Billion USD | 0.18% |
| 2022 Q2 | 128.49 Billion USD | 1.26% |
| 2022 FY | 121.51 Billion USD | -7.3% |
| 2022 Q4 | 121.51 Billion USD | -3.02% |
| 2022 Q3 | 125.29 Billion USD | -2.49% |
| 2022 Q1 | 126.89 Billion USD | -3.2% |
| 2021 Q1 | 136.76 Billion USD | -0.51% |
| 2021 FY | 131.09 Billion USD | -4.64% |
| 2021 Q2 | 135.37 Billion USD | -1.02% |
| 2021 Q3 | 135.28 Billion USD | -0.07% |
| 2021 Q4 | 131.09 Billion USD | -3.1% |
| 2020 Q2 | 134.79 Billion USD | 36.69% |
| 2020 Q3 | 134.33 Billion USD | -0.35% |
| 2020 Q4 | 137.46 Billion USD | 2.33% |
| 2020 FY | 137.46 Billion USD | 41.3% |
| 2020 Q1 | 98.61 Billion USD | 1.36% |
| 2019 Q2 | 65.7 Billion USD | 1.72% |
| 2019 Q4 | 97.28 Billion USD | 43.77% |
| 2019 FY | 97.28 Billion USD | 43.5% |
| 2019 Q1 | 64.59 Billion USD | -4.72% |
| 2019 Q3 | 67.66 Billion USD | 2.98% |
| 2018 Q2 | 65.01 Billion USD | -1.17% |
| 2018 FY | 67.79 Billion USD | 3.21% |
| 2018 Q4 | 67.79 Billion USD | -1.86% |
| 2018 Q3 | 69.08 Billion USD | 6.26% |
| 2018 Q1 | 65.78 Billion USD | 0.15% |
| 2017 Q3 | 62.15 Billion USD | 1.92% |
| 2017 Q4 | 65.68 Billion USD | 5.69% |
| 2017 Q1 | 60.66 Billion USD | -1.3% |
| 2017 Q2 | 60.98 Billion USD | 0.53% |
| 2017 FY | 65.68 Billion USD | 6.88% |
| 2016 Q1 | 49.07 Billion USD | -0.06% |
| 2016 FY | 61.46 Billion USD | 25.17% |
| 2016 Q3 | 60.15 Billion USD | -2.3% |
| 2016 Q4 | 61.46 Billion USD | 2.17% |
| 2016 Q2 | 61.57 Billion USD | 25.46% |
| 2015 Q2 | 48.35 Billion USD | 90.94% |
| 2015 FY | 49.1 Billion USD | 90.29% |
| 2015 Q1 | 25.32 Billion USD | -1.87% |
| 2015 Q4 | 49.1 Billion USD | -1.73% |
| 2015 Q3 | 49.96 Billion USD | 3.35% |
| 2014 Q3 | 23.8 Billion USD | -0.08% |
| 2014 Q4 | 25.8 Billion USD | 8.38% |
| 2014 Q2 | 23.82 Billion USD | -0.56% |
| 2014 Q1 | 23.96 Billion USD | -3.02% |
| 2014 FY | 25.8 Billion USD | 4.45% |
| 2013 FY | 24.7 Billion USD | 4.49% |
| 2013 Q1 | 24.21 Billion USD | 2.4% |
| 2013 Q2 | 24.35 Billion USD | 0.58% |
| 2013 Q3 | 24.67 Billion USD | 1.33% |
| 2013 Q4 | 24.7 Billion USD | 0.13% |
| 2012 FY | 23.64 Billion USD | 218.09% |
| 2012 Q4 | 23.64 Billion USD | 234.86% |
| 2012 Q3 | 7.06 Billion USD | 13.81% |
| 2012 Q2 | 6.2 Billion USD | -10.22% |
| 2012 Q1 | 6.91 Billion USD | -7.03% |
| 2011 FY | 7.43 Billion USD | 36.85% |
| 2011 Q4 | 7.43 Billion USD | 0.0% |
| 2010 FY | 5.43 Billion USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Bristol-Myers Squibb Company | 65.67 Billion USD | -89.29% |
| Bristol-Myers Squibb Company Ce | 65.67 Billion USD | -89.29% |
| Johnson & Johnson | 98.78 Billion USD | -25.844% |
| Eli Lilly and Company | 53.14 Billion USD | -133.925% |
| Merck & Co., Inc. | 69.04 Billion USD | -80.061% |
| Novartis AG | 53.19 Billion USD | -133.695% |
| Organon & Co. | 12.12 Billion USD | -925.016% |
| Pfizer Inc. | 137.21 Billion USD | 9.401% |